513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Dolby reported fourth-quarter fiscal 2024 revenue of $305 million, up from $291 million a year earlier, and GAAP diluted earnings of $0.61 per share versus $0.09. For the full fiscal year, revenue fell to $1.27 billion from $1.30 billion, while GAAP diluted EPS rose to $2.69 from $2.05. The company also gave fiscal 2025 revenue guidance of $1.33 billion to $1.39 billion and entered a $250 million revolving credit facility with Bank of America, with no amount drawn at closing.
Q4 fiscal 2024 revenue $305 million vs. $291 million a year earlier; GAAP diluted EPS $0.61 vs. $0.09
Full fiscal 2024 revenue $1.27 billion vs. $1.30 billion; GAAP diluted EPS $2.69 vs. $2.05
Fiscal 2025 guidance: total revenue $1.33 billion to $1.39 billion; GAAP diluted EPS $2.43 to $2.58
Credit Agreement signed November 14, 2024: $250 million unsecured revolver plus $150 million uncommitted incremental capacity; $0.33 per share dividend payable December 10, 2024
On November 13, 2024, Adtalem's board unanimously elected President and CEO Stephen W. Beard as chairman, so he now holds both roles, succeeding Michael W. Malafronte, who remains on the board as lead independent director. The same day, shareholders elected all ten director nominees and approved the PricewaterhouseCoopers LLP auditor ratification and an advisory vote on executive compensation. The filing names Adtalem Global Education Inc. (NYSE: ATGE), not Covista Inc. (CVSA) as shown in the filing header.
November 13, 2024: board unanimously elected CEO Stephen W. Beard as chairman, effective immediately; Malafronte becomes lead independent director.
Annual meeting, November 13, 2024: all ten directors elected; Beard received 33,253,740 votes for and 66,330 against.
PricewaterhouseCoopers LLP ratification passed with 33,848,340 for and 629,766 against; advisory executive pay vote passed with 31,744,452 for and 847,326 against.
Energizer reported fiscal 2024 net sales of $2,887.0 million, down 2.5% from $2,959.7 million, while adjusted diluted EPS rose to $3.32 from $3.09. Reported net earnings fell to $38.1 million from $140.5 million, mainly due to a $110.6 million non-cash impairment of intangible assets. The company guided fiscal 2025 adjusted EBITDA to $625 million to $645 million and adjusted EPS to $3.45 to $3.65, and its board approved a new buyback of up to 7.5 million shares.
Fiscal 2024 net sales were $2,887.0 million, down 2.5%; organic sales declined 2.2%
Fiscal 2024 reported diluted EPS was $0.52 versus $1.94; adjusted diluted EPS was $3.32 versus $3.09
Fiscal 2025 outlook: adjusted EBITDA of $625 million to $645 million and adjusted EPS of $3.45 to $3.65
Board approved a new share repurchase program of up to 7.5 million shares on November 18, 2024, replacing the prior authorization
Cytokinetics granted Bayer Consumer Care AG an exclusive license to develop and commercialize aficamten in Japan under an agreement signed November 18, 2024. Cytokinetics will receive a €50 million upfront payment, with additional milestone and royalty payments possible, while it keeps the right to run certain clinical trials in Japan.
Upfront payment of €50 million from Bayer
Milestone payments of up to €90 million tied to clinical and launch events in hypertrophic cardiomyopathy
Commercial milestones of up to €490 million plus tiered royalties on Japan net sales, from the high teens to the low thirties percent
Agreement dated November 18, 2024; full text to be filed with the 2024 Form 10-K
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.